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ABSTRACT
In vitro transcription has proven to be a successful tool for preparation of functional RNAs, especially in the tRNA field, in
which, despite the absence of post-transcriptional modifications, transcripts are correctly folded and functionally active. Human
mitochondrial (mt) tRNALys deviates from this principle and folds into various inactive conformations, due to the absence of the
post-transcriptional modification m1A9 which hinders base-pairing with U64 in the native tRNA. Unavailability of a functional
transcript is a serious drawback for structure/function investigations as well as in deciphering the molecular mechanisms by
which point mutations in the mt tRNALys gene cause severe human disorders. Here, we show that an engineered in vitro
transcribed “pseudo-WT“ tRNALys variant is efficiently recognized by lysyl-tRNA synthetase and can substitute for the WT tRNA
as a valuable reference molecule. This has been exploited in a systematic analysis of the effects on aminoacylation of nine
pathology-related mutations described so far. The sole mutation located in a loop of the tRNA secondary structure, A8344G,
does not affect aminoacylation efficiency. Out of eight mutations located in helical domains converting canonical Watson–Crick
pairs into G–U pairs or C•A mismatches, six have no effect on aminoacylation (A8296G, U8316C, G8342A, U8356C, U8362G,
G8363A), and two lead to drastic decreases (5000- to 7000-fold) in lysylation efficiencies (G8313A and G8328A). This
screening, allowing for analysis of the primary impact level of all mutations affecting one tRNA under comparable conditions,
indicates distinct molecular origins for different disorders.
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INTRODUCTION
Specific aminoacylation of transfer RNAs (tRNA) by their
cognate aminoacyl-tRNA synthetases (aaRS) is a key step in
translation of genetic information. Rules governing the rec-
ognition process between the partner macromolecules have
been well studied for a large number of prokaryotic and
cytosolic eukaryotic systems (for review, see Giegé et al.
1998b; McClain 1993a, 1995; Saks et al. 1994; Giegé and
Frugier 2003). On the other hand, far less is known for
mitochondrial (mt) tRNAs and aaRSs, especially from hu-
man and mammals in general (Florentz and Sissler 2003).
This is a drawback not only in the frame of fundamental
knowledge about these mt aminoacylation systems but also
in regard to understanding molecular mechanisms under-
lying numerous human disorders. Over the past 15 years, an
increasing number of point mutations within human mt
tRNA genes have been correlated with severe neurodegen-
erative and/or muscular disorders (e.g., Larsson and Clay-
ton 1995; Schon et al. 1997; Wallace 1999; DiMauro and
Andreu 2000; Florentz and Sissler 2001). More than 90
point mutations have been reported so far, located in 21 of
the 22 mt tRNA genes (e.g., Kogelnik et al. 1998; Servidei
2002). A large majority of these mutations lead to a decrease
in the rate of mitochondrial protein synthesis. However, the
detailed molecular level at which each mutation interferes
with the tRNA lifecycle remains mostly unknown. tRNA
aminoacylation being the key step of protein biosynthesis, a
systematic investigation of the effects of point mutations in
tRNAs on this process would allow for a straightforward
comparison.
As opposed to studies on classical tRNAs, investigation of
human mt tRNA aminoacylation systems suffers from a
series of limitations linked to intrinsic properties of mito-
chondria. Their heteroplasmic status, that is, the presence of
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both WT and mutant DNA in the same cell, requires the
creation of individual trans-mitochondrial cell-lines for in
vivo investigation of each mutation (King and Attardi
1989). Although such cells allowed for evaluation of steady-
state levels of aminoacylation (for review, see by Enriquez
and Attardi 1996; Florentz and Sissler 2003), their creation
is difficult so that only a handful of mutations could be
analyzed in such a way so far. Moreover, the variety of cell
types used as a basis for creation of cybrids (e.g., HeLa,
osteosarcoma, lymphoblasts) does not allow for straightfor-
ward comparisons, due to variations in nuclear back-
grounds (Jacobs and Holt 2000). Ex vivo analyses, based on
extraction of a specific tRNA from cultured cells or from
biopsies, are limited by the quantities of accessible material.
This has only been reported in two cases so far (Yasukawa
et al. 2001; Park et al. 2003). The alternative approach con-
sists of producing tRNA through in vitro transcription of
cloned WT and mutated human mt tRNA genes as has been
the case for cohorts of canonical tRNAs (Giegé et al. 1998b;
Giegé and Frugier 2003). Such an approach, based on
tRNAs deprived of post-transcriptional modifications, has
been validated over the past 20 years for a vast majority of
aminoacylation systems from various organisms and al-
lowed, for example, the deciphering of aminoacylation
identity elements in specific tRNAs. Interestingly, the in
vitro approach leads to similar results to those obtained by
in vivo methods (for review, see McClain 1993b; Giegé et al.
1998b).
In regard of human mt tRNAs, the approach based on the
in vitro synthesis of transcripts was found to be efficient and
has already been explored in the case of isoleucine-specific
(Degoul et al. 1998; Kelley et al. 2000, 2001) and serine-
specific (Shimada et al. 2001) tRNAs but lead to a number
of difficulties for other mt tRNAs. Indeed, at least those
transcripts specific for lysine (Helm et al. 1998; Tolkunova
et al. 2000) and phenylalanine (Bullard et al. 1999) turned
out to be unsatisfactory substrates for aaRSs due to unfa-
vorable folding of the RNAs. In the case of tRNALeu(UUR),
aminoacylation is possible despite structural flexibility of
the transcript compared with native tRNA (Park et al. 2003;
Sohm et al. 2003; Wittenhagen et al. 2003). Because in vitro
transcription remains the sole conceivable straightforward
approach to access human mt tRNAs (wild type and mu-
tants) and to perform rigorous systematic comparative
analysis of tRNA variants for a given function (e.g., matu-
ration, aminoacylation), functional in vitro transcripts need
to be engineered.
Here, we consider the specific case of human mt tRNALys.
Previous work showed that an in vitro transcript of this
tRNA does not fold into a functional cloverleaf but into
alternative extended bulged hairpins (Fig. 1A; Helm et al.
1998), and is poorly aminoacylated in the presence of a
human mt crude enzymatic extract (Helm et al. 1998) or of
an overexpressed and purified mt LysRS (Tolkunova et al.
2000). The requirement of a single post-transcriptional
modification for cloverleaf folding of tRNALys was con-
firmed by synthesis and structural analysis of a chimeric
tRNALys, which displays a unique modified base, a methyl-
ated adenosine at position 9 (Fig. 1B; Helm et al. 1999b).
This modification impairs the formation of a Watson–Crick
base pair between nucleotides 9 and 64 responsible for the
extension of the amino acid acceptor stem within the tran-
script. Interestingly, the structural chaperone effect of m1A9
modification can be simulated by mutating either nucleo-
tide 9 or nucleotide 64 (provided base-pairing between resi-
dues 64–50 is conserved; Helm et al. 1998). Such variants,
carrying an altered base pair at position 50–64 replacing
A50–U64 by U50–A64 (Ki) or by G50–C64 (Ke), adopt the
expected cloverleaf folding, as demonstrated by enzymatic
and chemical probing (Fig. 1C; Helm et al. 1998).
Here, it is shown that these engineered variants are active
substrates for LysRS and that they represent valuable refer-
ence molecules for further investigation of tRNALys nucleo-
tides important for aminoacylation. The lysylation system
has further been explored in a systematic investigation of
the full set of mutations described so far for the human mt
tRNALys gene, a hot spot for pathology-related mutations.
Results are discussed both in the frame of molecular mecha-
nisms involved in the expression of the diseases, and in the
frame of understanding lysylation rules in human mito-
chondria.
RESULTS
Setting up an efficient lysylation system based on in
vitro transcripts
The in vitro transcribed structural variants Ke and Ki of
human mt tRNALys (Fig. 1C) were previously shown to
adopt the expected cloverleaf secondary structure (Helm et
al. 1998). As the presence of a C-residue at the first position
of tRNALys highly limits yields of in vitro transcription, a G
being most favorable for T7 RNA polymerase efficiency
(Sampson and Uhlenbeck 1988), new synthetic genes have
been cloned. They consist of the T7 promoter followed by
a hammerhead ribozyme (Rz; Fechter et al. 1998) and the
tRNA gene, leading to wild-type (Rz-Kwt) and “pseudo-
WT” (Rz-Ke and Rz-Ki) transcripts. These transcripts were
tested for their lysylation properties compared with those of
human mt native WT tRNALys (extracted from cybrid cell
lines, see Experimental Procedures). Because it is laborious
to obtain native tRNAs in the large amount required for
determination of kinetic parameters, only charging levels
have been established for this initial investigation (Fig. 2).
The aminoacylation assays were performed in the presence
of human cytosolic lysyl-tRNA synthetase. Both cytosolic
and mt enzymes are encoded by the same nuclear gene and
differ in their mature versions only by 21 to 49 (over 601)
amino acids at their N terminus (Tolkunova et al. 2000).
Although Rz-Kwt, the transcript which folds into ex-
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tended hairpin structures, is poorly aminoacylated, Rz-Ke
(with A50–U64 replaced by G50–C64) and Rz-Ki (with
A50–U64 replaced by U50–A64) become active substrates
for human LysRS with 42% ± 2% charging levels, an activ-
ity close to the 57 ± 2% measured for native mt WT
tRNALys. Rz-Ke and Rz-Ki display identical functional
properties, demonstrating that the residues paired at posi-
tions 50 and 64 do not influence recognition by LysRS.
Effect of MERRF mutation A8344G on aminoacylation
levels and on tRNALys structure
Among the 13 pathology-related mutations described
within the mt tRNALys gene, transition A8344G,2 correlated
with the MERRF syndrome (Shoffner et al. 1990; Servidei
2002), is the most prevalent mutation. This mutation, lo-
cated in the T-loop of the cloverleaf-folded tRNA at posi-
tion 55 (conventional tRNA numbering, see Fig. 5 below),
has been introduced into Rz-Ke and Rz-Ki, leading to Rz-
Kem and Rz-Kim. Aminoacylation properties as well as
structural properties have been investigated for these vari-
ants. Interestingly, both Rz-Kem and Rz-Kim are aminoac-
ylated to levels similar to the corresponding pseudo-WT
transcripts (Fig. 3). Under optimal LysRS concentrations,
all four transcripts are charged up to 42 ± 2% (Fig. 3).
The aminoacylation properties of native human mt
tRNALys, either wild type or with the MERRF mutation, have
been established. tRNAs have been extracted from a specific
couple of cybrid cell lines (R2–1A and R1–C3, respectively)
by hybridization to a complementary biotinylated oligo-
nucleotide. The yield of pure native tRNALys species is ex-
tremely low (0.3 µg of pure wild type or MERRF-mutated
tRNAs were extracted from ∼1 or ∼1.3 L of corresponding
adherent cell cultures, respectively), so that only charging
2Numbering is according to location in the mitochondrial genome;
Anderson et al. 1981.
FIGURE 1. Human mitochondrial wild-type and pseudo-WT tRNALys transcripts. (A) Determined secondary structures of human mt wild-type
tRNALys transcript (Kwt; Helm et al. 1998). (B) Experimental secondary cloverleaf structures of native mt tRNALys (displaying the six post-
transcriptional modifications, abbreviated in the conventional way; Sprinzl et al. 1998) and of a chimeric tRNALys methylated at position N1 of
A9 as sole post-transcriptional modification (Helm et al. 1999b). (C) Pseudo-WT in vitro transcribed tRNALys derivatives Ke and Ki. tRNA
domains are labeled for Ke. Structural mutations introduced at positions 50 and 64 (indicated by gray circles) prevent alternate folding into
extended hairpin (black crosses; Helm et al. 1998).
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levels could be established. Figure 3 shows that both native
tRNALyss are lysylated to about the same level (57 ± 2%).
Thus, as is the case for transcripts, no substantial effect of
the MERRF mutation is observed on aminoacylation of na-
tive tRNAs.
Possible structural effects of MERRF mutation have been
sought. End-labeled transcripts were submitted to chemical
probing with DEPC and Pb(OAc)2, as previously performed
for Kwt, Ke, and Ki (Helm et al. 1998). Autoradiographies
of comparative structural probing experiments on Ke, Ki,
Kem, and Kim are displayed in Figure 4A. Cleavages were
categorized weak (white), moderate (gray), or strong
(black), and the results for individual nucleotides are sum-
marized in Figure 4B. The reactivities to probes of all four
transcripts were virtually identical. The probes failed to de-
tect any significant difference between the pseudo-WT ana-
logs of mt tRNALys on one hand (Ki and Ke), and the
“pseudo-MERRF” analogs on the other hand (Kim and
Kem).
Systematic mutagenic analysis
So far, 10 mutations in the human mt tRNALys gene have
been reported to be related to pathologies such as muscular
disorders, encephalopathies, deafness, ophthalmoplegia, or
diabetes (Kogelnik et al. 1998; Servidei 2002). A8348G, a
polymorphism unrelated to disorders, was also described
(Ingman et al. 2000). These 11 mutations have been indi-
vidually introduced into the pseudo-wild-type Rz-Ki se-
quence (Fig. 5). Only the variant with transition T8355C
could not be prepared because the mutation overlaps with
the Rz-Ki structural mutation. An additional transcript has
been constructed with a sequence modification in the an-
ticodon central position (T8324A, or U35A in classical
tRNA nomenclature). This mutation was hypothesized to
have a strongly deleterious effect on the lysylation reaction
because nucleotides U35 and U36 from the anticodon trip-
let are known as major lysine specific identity elements in
canonical lysylation systems (e.g., in Escherichia coli [Mc-
Clain et al. 1990; Normanly et al. 1990; Tamura et al. 1992]
and human cytosolic tRNALys [Stello et al. 1999]). Three
mutations are located in loops (MERRF mutation A8344G,
polymorphism A8348G, and the rationally designed muta-
tion in the anticodon triplet). All other mutations are lo-
cated in stems.
All transcripts have been tested for their ability to be
lysylated. Kinetic parameters are presented in Table 1 (right
part). As anticipated, the polymorphic mutation (A8348G)
in the T-loop has no significant effect on aminoacylation,
with a charging level of 60% (data not shown) and a neg-
ligible loss in aminoacylation efficiency. Mutation within
the anticodon triplet, replacing U35 by A35, lead to a drastic
decrease in lysylation efficiency (∼6000-fold). These two
variants can thus be considered as positive and negative
controls in the lysylation reaction. The nine pathology-re-
lated mutants (including the MERRF-related A8344G mu-
tation discussed above) have aminoacylation properties
ranking between these substrates. For six of them (A8296G,
T8316C, G8342A, A8344G, T8356C, and G8363A), amino-
acylation is not significantly impaired by the mutation, with
charging levels between 20% and 50% (data not shown)
and, at most, a fourfold loss of catalytic efficiency. A small
(2.8-fold) gain in efficiency is observed for the MERRF-
related mutant A8344G (gain = 1/L). Variant T8362G
shows a 10-fold decrease in efficiency. The two remaining
variants, G8313A and G8328A, drastically impair lysylation.
Charging levels are <1% (data not shown), and losses in
catalytic efficiencies reach 4900- and 7000-fold. This poor
charging did not allow for direct establishment of individual
kinetic parameters kcat and KM for these two variants.
Mutations with low effects on aminoacylation are mainly
located in the acceptor- and T-stems of the tRNA and at the
upper part of the anticodon stem (Table 1, left). These
mutations can be segregated into two categories from a
mechanistic point of view because some have unaffected
FIGURE 2. From inactive to active in vitro transcribed human mt
tRNALys. Charging levels, determined with human LysRS at 37°C, are
expressed as percentages of charged tRNA versus total amount of
specific tRNA per experiment. Rz-Kwt, Rz-Ke, and Rz-Ki correspond
to in vitro transcribed wild-type and structural variants of tRNALys,
respectively, purified to single nucleotide resolution on polyacryl-
amide/urea gels. Purified native wild-type mt tRNALys (by hybridiza-
tion to a specific biotinylated oligonucleotide) form the positive con-
trol.
FIGURE 3. Effect of MERRF (A8344G) mutation on aminoacylation.
Charging levels of wild type or pseudo-WT (Rz-Ke and Rz-Ki) versus
MERRF or pseudo-MERRF (Rz-Kem and Rz-Kim) tRNAs. Native
wild-type and MERRF-mutated mt tRNALys were extracted from mi-
tochondria of R2–1A and R1–C3 cybrid cells (see Experimental Pro-
cedures) using biotinylated oligonucleotides complementary to the 3
part of the tRNA. Rz- stands for self-cleaved in vitro transcribed
tRNAs.
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kinetic parameters kcat and KM (A8296G, G8342A, A8344G,
G8363A), whereas others have both a decrease in kcat and in
KM (fourfold to 10-fold), leading also to unaffected amino-
acylation efficiencies (T8316C, T8356C). Interestingly, both
mutations A8296G and T8362G concern the same base pair
but lead to low but significant differences in effects on ami-
noacylation. Mutation A8296G, converting the A2–U71
pair into G2–U71 has no effect, whereas mutation T8362G,
leading to an A2•G71 mismatch, leads to a 10-fold loss in
lysylation efficiency. This shows that LysRS is sensitive to
some extent to the structural integrity of base pair 2–71
rather than to the nature of the nucleotides present at these
positions. Mutations with large negative effects are located
within the anticodon domain and within the D-stem (Table
1, left).
DISCUSSION
From inactive to active in vitro transcribed human
mitochondrial tRNALys
In the present work, in vitro transcription was used to pro-
duce active molecules despite the absence of post-transcrip-
tional modification required to produce the canonical sec-
ondary structure. In the specific case of tRNALys, the ex-
tremely low aminoacylation capacity of the wild-type in
vitro transcript has been overcome by molecular engineer-
ing, leading to an efficient substrate for human LysRS. Ex-
change of a single Watson–Crick pair by an alternative Wat-
son–Crick pair within the tRNA T-stem simulates the struc-
tural chaperone effect of post-transcriptional modification
m1A9, favoring the cloverleaf structure (Helm et al. 1999b).
FIGURE 4. Effect of MERRF mutation on the structure of in vitro transcribed tRNAs. (A) Autoradiographs of 15% denaturing polyacrylamide
gels of chemical probing experiments. G indicates RNase T1 ladder; L, alkaline ladder; and C, control incubation without probe. (Top) Structural
probing experiments with lead acetate (Pb(OAc)2). 5-Labeled tRNAs are incubated at 25°C in 20 µL of 40 mM Tris-HCl (pH 7.5), 10 mM MgCl2,
40 mM NaCl, and 0.1 µg/µL unlabeled tRNA without (C) or with 0.15 mM Pb(OAc)2 for 10 min (1), 20 min (2), or 30 min (3). (Bottom) Chemical
probing with diethylpyrocarbonate (DEPC). N, SD, and D stand for native, semi-denaturating, and denaturating conditions, respectively.
5-Labeled tRNAs are incubated for 40 min without (C) or with 5% (v/v) DEPC (N, SD, D) in 50 mM sodium cacodylate with 10 mM MgCl2
and 300 mM KCl (C, N) or with 1 mM EDTA (SD, D). Incubation was performed for 4 min at 60°C for denaturating condition (D). (B) Chemical
probing patterns on cloverleaf structures of pseudo-WT (Ke and Ki) and pseudo-MERRF (Kem and Kim) transcripts. Structural mutations (at
position 50–64) and MERRF mutation (at position 55) are highlighted in bold. Arrowheads correspond to positions cleaved by probes (Pb(OAc)2
and DEPC). Cleavages are categorized weak (white), modest (gray), or strong (black).
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Two pseudo-WT ribozyme-derived transcripts, Rz-Ki and
Rz-Ke, with structural mutations A50–U64→ U50–A64 or
A50–U64 → G50–C64, respectively, become lysylated with
aminoacylation capacities significantly increased compared
with WT tRNALys transcript Rz-Kwt, close to those of na-
tive tRNALys extracted from mitochondria. As the two base
pair exchanges lead to identical functional effects, and the
corresponding nucleotide positions have not been shown in
tRNALys from other species to be involved in LysRS recog-
nition and aminoacylation efficiency, both Rz-Ki and Rz-Ke
can be used as reference molecules for further functional
exploration of tRNALys.
This has been further confirmed in the case of Rz-Ki by the
aminoacylation properties of four variants, namely, those with
the polymorphism A8348G, the rationally designed mutation
in the anticodon triplet, and the two pathology-related muta-
tions A8344G and G8313A. Polymorphic mutations have been
discovered by comparing mt DNA sequences among large
human populations and have been explored to reconstruct
human prehistory and population movements (e.g., Allen and
Raven 1996; Ingman et al. 2000). Such mutations are assumed
to be neutral in molecular and phenotype effects. We show
here that this is indeed the case for mutation A8348G in regard
to aminoacylation properties of the corresponding Rz-Ki de-
rivative. Mutating the anticodon triplet was expected to have a
strong negative effect on lysylation. Although aminoacylation
identity elements for the human mt lysine system were not
explored so far, it could be foreseen by analogy with known
lysylation systems (McClain et al. 1990; Tamura et al. 1992;
Stello et al. 1999) and on the basis of the general concept that
major identity elements are conserved among species (Giegé et
al. 1998b; Giegé and Frugier 2003), that mutating the central
residue of the anticodon triplet would be detrimental to ami-
noacylation. Indeed, replacing U35 by A35 in the Rz-Ki frame-
work leads to a ∼6000-fold loss in aminoacylation efficiency,
demonstrating that the initial replacement of A50–U64 by
U50–A64 does not interfere with the expression of identity
elements in the tRNA scaffold. Finally, two pathology-related
mutations within tRNALys have already been investigated for
their impact on lysylation by approaches not including in vitro
transcribed tRNAs. The impact of MERRF mutation A8344G
has been tested by an in vitro approach based on purification
of low amounts of native WT tRNALys and tRNALys with
mutation A8344G from large-scale cultures of HeLa-derived
cybrid cells (Yasukawa et al. 2001). Kinetic parameters for
lysylation of these natural, post-transcriptionally modified
molecules revealed a threefold increase in aminoacylation ef-
ficiency for the mutant tRNA compared with wild type. This is
in line with a 2.8-fold increase observed in the present work on
the Rz-Ki derivative with mutation A8344G compared with
Rz-Ki and with unchanged aminoacylation plateau levels for
native tRNALys species extracted from osteosarcoma-derived
cybrid cell lines. Further, in vivo measurements of aminoac-
ylation levels of mutated tRNALys have been performed both
for mutation A8344G (Enriquez et al. 1995; Börner et al. 2000)
and G8313A (Bacman et al. 2003). Although in the first case,
variable results were obtained according to the cell type used
(decrease in aminoacylation in osteosarcoma-derived cybrid
cell-lines, no effect in biopsies), a strikingly negative effect of
mutation G8313A has been reported in cybrid cell-lines. This
result is in line with the 7000-fold loss in lysylation observed in
the present work for Rz-Ki derivative bearing second site mu-
tation G8313A. Based on these results, we conclude that the in
vitro transcribed derivative of tRNALys Rz-Ki can indeed be
considered as a pseudo-wild-type molecule, relevant for fur-
ther mutagenic analyses.
Variable impacts of pathology-related mutations
on lysylation
Ten mt tRNALys gene mutations have been reported to be
associated with phenotypically wide-ranging human disor-
FIGURE 5. Investigated mutations in human mitochondrial tRNALys.
Individual variants were prepared as derivatives of Rz-Ki, the pseudo-
WT tRNALys with U50–A64 pair instead of A50–U64 pair. The 10
reported pathological mutations (http://www.mitomap.org/) are indi-
cated in black; the dashed arrow represents the one not investigated
because it overlaps the structural mutations. Control molecules, indi-
cated in gray, are either the polymorphic A8348G mutation (positive
control) or the U8324A sequence variation (which alters a major lysine
identity element, negative control). Numbering is either according to
the mt genome location (bold characters, for mutations; Anderson et
al. 1981) or according to the conventional tRNA annotation (small
numbers; Sprinzl et al. 1998). Related pathologies are abbreviated as
follows: DEAF, maternally inherited deafness or aminoglycoside-in-
duced deafness; DMDF, diabetes mellitus and deafness; EM, encepha-
lomyopathy; LS, Leigh syndrome; MELAS, mitochondrial encephalo-
myopathy, lactic acidosis, stroke-like episodes; MERRF, myoclonic
epilepsy and ragged red fibers; MICM, maternal inherited cardiomy-
opathy; MNGIE, mitochondrial neurogastrointestinal encephalomy-
opathy; MS, myoclonic seizures; PEO, progressive external ophthal-
moplegia; and SM, skeletal myopathy.
Sissler et al.
846 RNA, Vol. 10, No. 5
ders. Nine could be comparatively analyzed in regard to
their effect on aminoacylation of in vitro transcripts. They
segregate into two categories, with seven leading to little
effect on aminoacylation (<10-fold loss in aminoacylation
efficiency) and two (mutations G8313A and G8328A) lead-
ing to severe decreases (4900- to 7000-fold losses in effi-
ciency). These large differences suggest that a defect in ami-
noacylation efficiency would not be a common primary
molecular impact of pathology-related mutations in tRNALys.
However, it cannot be ruled out that even a weak effect on
aminoacylation, amplified by additional molecular events,
might be sufficient to contribute to the disease status. Simi-
lar conclusions have been drawn from aminoacylation stud-
ies performed on tRNAIle mutations (Kelley et al. 2000,
2001) and tRNALeu(UUR) mutations (Sohm et al. 2003). As
alternatives to aminoacylation, the impact of individual
mutations in various tRNAs were found at other functional
levels, including transcription, maturation, post-transcrip-
tional modification, stability, binding to elongation factor
EF-Tu, and codon reading (for review, see Florentz et al.
2003). In the specific case of tRNALys mutations, only
MERRF mutation A8344G has been investigated at different
levels. This mutation does not affect mitochondrial tran-
scription (Hanna et al. 1995; Masucci et al. 1995). It does
not affect the global post-transcriptional modification pat-
tern of the tRNA (Helm et al. 1999a), except modification
at nucleotide 34, which is completely abolished (Yasukawa
et al. 2000). The detailed chemical probing analysis in so-
lution performed herein shows that MERRF-mutation
A8344G does not alter the tRNA structure. However, the
stability of the mutated tRNA is reduced (Enriquez et al.
1995; Yasukawa et al. 2000). Further, its interaction with
EF-Tu is decreased (Yasukawa et al. 2001), and most im-
portant, its capacity to read the lysine codons is strongly
affected (Yasukawa et al. 2001). For most other mutations
affecting the human mt tRNALys gene, no information is
available as to primary molecular impact. Access to in vitro
transcripts has allowed a systematic investigation of the ef-
fect of individual mutations on aminoacylation and should
allow a number of other possibilities, including maturation,
stability, structure, and recognition by elongation factor, to
be investigated in a systematic way.
The comparative analysis of mutations within the same
tRNA also shows only partial correlation between the pri-
mary impact of the mutation and the phenotype of the
disorder. None of the four mutations correlated with
MERRF syndrome (G8363A, T8356C, A8344G, A8296G) or
either of the two mutations correlated with deafness
(G8363A, A8296G) affect tRNALys aminoacylation. On the
other hand, two mutations linked to encephalopathies do
affect this reaction (G8313A and G8328A), whereas a third
one (T8316C, linked to MELAS) does not. MELAS syn-
drome correlates with mutation A3243G in tRNALeu(UUR),
in which it leads to a significant decrease in leucylation (see
Börner et al. 2000; Chomyn et al. 2000; Park et al. 2003;
Sohm et al. 2003). Thus, primary mechanisms leading to the
same disorder can be different according to the tRNA in
which the deleterious mutation occurs.
TABLE 1. Aminoacylation properties of in vitro transcribed pseudo-WT and variant human mt tRNALys in the presence of human LysRS
In vitro transcripts
tRNA
position
Wild-type
sequence
Mutated
sequence
kcat
(10−3 sec−1)
KM
(µM)
kcat/KM
(10−6 sec−1  nM−1) Loss
Reference molecule
Rz-Ki 50–64 (TS) A–U UA 12 4.0 3.0 1
Polymorphism
A8348G 59 (AccS) A G 11.8 2.4 4.9 0.6
Anticodon triplet mutation
T8324A 35 (ACL) U A nd nd *0.49 10−3 6100
Disease-related mutations
A8296G 2 (AccS) A–U GU 10.2 4.4 2.3 1.3
G8313A 24 (DS) C–G CA nd nd *0.43 10−3 7000
T8316C 27 (ACS) U–A CA 2.4 1.5 1.8 2.0
G8328A 39 (ACS) C–G CA nd nd *0.61 10−3 4900
G8342A 53 (TL) G–C AC 8.5 4.1 2.1 1.4
A8344G 55 (TS) A G 14.3 1.7 8.4 0.3
T8356C 65 (TS) A–U AC 0.9 1.2 0.75 4.0
T8362G 71 (AccS) A–U AG nd nd *0.3 10
G8363A 72 (AccS) C–G CA 22.9 10.3 2.2 1.4
Names of the tRNA variants, affected tRNA positions (conventional tRNA numbering, according to Sprinzl et al. 1998), and sequence changes
are given in the left part of the table. tRNA structural domains are abbreviated as follows: AccS, acceptor stem; TS, T-stem; DS, D-stem;
ACS, anticodon stem; and TL, T-loop. Aminoacylation parameters measured at 25°C in the presence of human cytosolic LysRS are presented
on the right. Loss-values (L) are defined as ratio (kcat/KM)Rz-Kl/(kcat/KM)variant. L-values varied by <10%.
*Ratios kcat/KM were determined directly as described (Schulman and Pelka 1988).
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Rules governing lysylation of human
mitochondrial tRNALys
Several observations from the present work allow one to
distinguish features within human mt tRNALys regarding
their importance for lysylation. Comparison of aminoacyla-
tion properties of native tRNA extracted from human mi-
tochondria with in vitro transcripts defines the contribution
of post-transcriptional base modifications to the aminoac-
ylation process. The natural tRNA was shown to possess six
modifications: m1A9, m2G10, 27, 28, sU*34, and t6A37
(Helm et al. 1998; Yasukawa et al. 2001). As already dis-
cussed, m1A9 plays an essential role as a structural chaper-
one, promoting cloverleaf folding. The other modifications,
especially those in helical domains, probably also contribute
in a limited way to structure stabilization, as was shown for
other tRNAs (Agris 1996), and in consequence improve
aminoacylation efficiency. Such considerations may explain
the slight difference in aminoacylation plateaus observed for
the tRNALys transcripts Rz-Ke and Rz-Ki compared with
native tRNALys. Modifications of anticodon loop nucleo-
tides of tRNAs can contribute directly to aminoacylation
identity (Giegé et al. 1998b; Giegé and Frugier 2003). This
is probably not the case for human mt tRNALys, as can be
deduced from aminoacylation properties of native wild type
and native MERRF mutated tRNALys (Yasukawa et al.
2001). Both tRNAs are lysylated to similar levels (this work)
with very similar efficiencies (Yasukawa et al. 2001) despite
the complete absence of modification sU*34 in the MERRF
derivative (Yasukawa et al. 2000). In the crystal structures
available of lysyl-tRNA synthetase from T. thermophilus
complexed either to fully modified E. coli tRNALys or to in
vitro transcribed T. thermophilus tRNALys (Cusack et al.
1996), the mode of binding of the anticodon loops is the
same, and both mnm5s2U or a nonmodified C-residue can
be accommodated in the anticodon binding site of the en-
zyme. Although access to comparative kinetic parameters of
transcripts and native tRNALys are not available (due to the
difficulty in purifying sufficient quantities of native tRNAs),
the above data lead to the conclusion that, beyond the ma-
jor structural role of m1A9, post-transcriptional modifica-
tions make no major contribution to the lysylation prop-
erties of human mt tRNALys. This is in line with the low
decrease (10-fold) in kcat/KM observed for human cytosolic
tRNALysIII transcribed in vitro compared with native tRNA
(Stello et al. 1999). In E. coli, post-transcriptional modifi-
cations make a more pronounced contribution because they
improve aminoacylation efficiency 140-fold (Tamura et al.
1992).
Mutagenesis of in vitro transcribed tRNAs has been ex-
plored intensively in a large number of aminoacylation sys-
tems with the goal of deciphering aminoacylation identity
elements (Giegé et al. 1998b; Giegé and Frugier 2003). As an
outcome of the investigation of the 11 tRNALys variants
investigated here, it can be concluded that the central U-
residue from the anticodon loop (U35) is a major lysylation
identity nucleotide. This was anticipated based on results
from all lysylation systems explored so far both in vitro
(Tamura et al. 1992; Shiba et al. 1997) and in vivo (McClain
et al. 1990; Normanly et al. 1990). It is also clear that
nucleotides 24 and 39 (and/or the base pairs in which they
are involved) in the D-stem and anticodon-stem respec-
tively, contribute in an essential way to lysylation. On the
other hand, nucleotides or base pairs involving nucleotides
2, 71, and 72 in the acceptor stem; nucleotide 27 in the
anticodon stem; nucleotides 50, 53, 64, 65 in the T-stem;
and nucleotides 53, 55, and 59 in the T-loop are only of
limited importance.
Interestingly, the mutations investigated here are distrib-
uted all over the secondary cloverleaf structure of the tRNA,
with only three mutations in loops and all others in stems.
Within stems, each mutation converts a classical Watson–
Crick pair into a weaker base pair. Eight mutations lead to
C•A, A•C, or A•G mismatches and one to a G•U weak pair.
Some drastically reduce aminoacylation; others do not af-
fect this process (Fig. 6A). Occurrence of mismatches of the
above type is not specific to tRNALys mutations, or to pa-
thology-related mutations, but is a general observation for
mt tRNA gene mutations (Florentz and Sissler 2001). These
mismatches are expected to destabilize helical domains to
some extent (Varani and McClain 2000). Because amino-
acylation of tRNAs by their cognate aminoacyl-tRNA syn-
thetase is sensitive to structural properties of the tRNA
(Giegé and Frugier 2003), some mismatches can be ex-
pected to interfere with the lysylation properties of the mt
tRNA. In an attempt to understand these distinct effects,
mutated nucleotides have been located within a three-di-
mensional tRNA structure (Fig. 6C–E). In absence of crys-
tallographic data for human mt tRNALys, the structure of
yeast tRNAAsp complexed to its cognate synthetase (Ruff et
al. 1991; Cavarelli et al. 1993) has been chosen as a model.
This structure is not expected to correspond exactly to that
of tRNALys, especially in regard of the D/T-loops interac-
tions, which obviously are different (the mt tRNA has a very
short D-loop of three nucleotides and an enlarged T-loop of
nine nucleotides; further, classical nucleotides G18, G19,
U56, and C57 allowing for tertiary interactions between the
two loops are missing). Both tRNALys and tRNAAsp are,
however, recognized by aminoacyl-tRNA synthetases be-
longing to the same subclass IIb of synthetases (Cusack et al.
1990; Eriani et al. 1990). Figure 6, C through E, highlights
that mutations affecting aminoacylation are all in the anti-
codon branch of the L-shaped three-dimensional structure,
along the same side of the molecule. These mutations are in
line with the single acceptor branch mutation leading to a
weak loss in aminoacylation efficiency. All other mutations
not affecting aminoacylation either are in the acceptor
branch or, if present in the anticodon branch, are located
on the opposite side.
The mechanisms by which both deleterious mutations,
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affecting highly conserved base pairs in mammalian mt
tRNALys sequences (Fig. 6B; Helm et al. 2000), interfere
with lysylation remain to be established. Mutations may
either remove identity elements or introduce antidetermi-
nants, hindering recognition by the cognate synthetase. In
both situations, direct contacts between the enzyme and its
substrate would be hindered. Alternatively, if the affected
nucleotides are not in direct contact with the synthetase,
their sequence variations may lead to perturbations of the
tRNA architectural frame, thus hindering signal transmis-
sion from the anticodon loop identity elements (in particu-
lar, the central anticodon triplet nucleotide) to the 3-end of
the tRNA, where aminoacylation takes place. Finally, mu-
tations with negative effects on aminoacylation may simply
remove essential permissive elements. These concepts, al-
ready described and illustrated for a number of canonical
tRNA aminoacylation systems (see Frugier et al. 1998; Giegé
et al. 1998a,b; Choi et al. 2003), now need to be tested
experimentally for mt tRNALys.
Conclusion and outlook
The present work demonstrates that despite the crucial re-
quirement of a post-transcriptional modification in human
mt tRNALys folding, it is possible to create well-folded in
vitro transcripts, efficient in aminoacylation, and thus to
explore the contribution of individual nucleotides on tRNA
structural and functional properties by second-site muta-
FIGURE 6. Structural insight on pathology-related mutations. (A) Summary of the effects of mutations on tRNALys aminoacylation efficiencies.
Values are from Table 1 and the color code is as follows: structural mutations introduced at positions 50 and 64, which prevent alternate folding
into extended hairpin (Helm et al. 1998), are indicated in green. Polymorphic mutation A8348G is in yellow. Neutral, mild, and highly deleterious
mutations are, respectively, in blue, pink, and magenta. (B) Sequence conservation of mammalian mt tRNALys genes (Helm et al. 2000) and
location of pathology-related mutations studied in the present work (arrowheads). The color code for arrowheads is as in A. (C–E) Location of
mutations in three-dimensional representations of the tRNA. The color code is the same as in parts A and B. Nucleotides complementary to
mutated positions and thus involved in base-pairing are in white. The model tRNA is a ribbon representation of the crystal structure of yeast
tRNAAsp (in its complexed form with AspRS; Ruff et al. 1991; Cavarelli et al. 1993). (E) Profile representation emphasizing the location of harmful
mutations within a same face of the tRNA. The CCA end is pointed toward the reader.
Aminoacylation of human mt tRNALys
www.rnajournal.org 849
genesis. Systematic exploration of aminoacylation proper-
ties of the full set of pathology-related and polymorphic
mutations in tRNALys represents an initial application of
such engineered substrates. It enlarges both our under-
standing of lysylation properties of a mt tRNA and of po-
tential molecular mechanisms underlying various human
disorders. It also offers new perspectives for exploring fur-
ther structural and functional properties of this tRNA and
of the related variants, including mischarging properties or,
formulated differently, the gain of function hypothesis in
mitochondrial disorders (Jacobs and Holt 2000). Experi-
ments are underway to fully decipher the lysine identity
elements and their mechanism of action.
From a theoretical point of view, most human mt tRNAs
have peculiar structural features (Helm et al. 2000; Florentz
et al. 2003), including weak base pairs; the presence of mis-
matches, unusual D-loop, and T-loop sizes; and the absence
of classical tertiary interactions. Engineered structural sta-
bilization of in vitro transcripts might represent a successful
approach to enable a systematic investigation of structural
and functional properties of any member of this tRNA fam-
ily and to screen for the effect of pathology-related muta-
tions on a simple basis, before undertaking indispensable
but laborious in vivo analyses.
EXPERIMENTAL PROCEDURES
Materials
Restriction enzymes were from New England Biolabs and T4 DNA
ligase from Boehringer-Mannheim. PCR-purified oligonucleotides
were from NAPS or Interactiva. GoldStar Taq DNA polymerase
was purchased from Eurogentech. Phage T7 RNA polymerase was
prepared from an overexpression clone according to the method
of Becker et al. (1996). Plasmid pM368 Hs-LysRS-HisTag encod-
ing the full-length human cytosolic LysRS (LysRS) was kindly
provided by Karin Musier-Forsyth (University of Minnesota, Min-
neapolis, MN). Initial cybrid cell lines R2–1A and R1–C3, display-
ing, respectively, wild-type and MERRF-mutated human mt DNA,
were kindly provided by Guiseppe Attardi and Anne Chomyn
(Caltech, Pasadena, CA).
Production of mitochondrial tRNAs by in
vitro transcription
Synthetic genes, corresponding to the T7 RNA polymerase pro-
moter followed by the human mt wild-type tRNALys gene (Kwt) or
variants Ke (G50–C64) and Ki (U50–A64), and terminating at a
BstN1 site, were previously constructed from overlapping and
complementary oligonucleotides and cloned into pTFMA as de-
scribed in (Helm et al. 1998). The synthetic gene corresponding to
the T7 promoter connected to the downstream sequence of a
hammerhead ribozyme (Fechter et al. 1998) followed by the hu-
man mt tRNALys sequence (Rz-Kwt) was also previously cloned
(Helm et al. 1999b). Mutated tRNAs, bearing in all cases the
A50U/U64A structural mutations and, respectively, mutation
A8296G, G8313A, T8316C, G8328A, G8342A, T8356C, T8362G,
G8363A (pathology-related mutations; numbering according to
the location in the mitochondrial DNA), A8348G (polymorphic
mutation), or T8324A (altering the anticodon triplet), were cloned
following the same protocol (Helm et al. 1999b). Clones Rz-Ke,
Rz-Ki, Rz-Kem, and Rz-Kim were derived from Rz-Kwt by PCR
amplification, using in all cases oligonucleotide 659 (5-CAC
CAAGCTTAATACGACTCACTATA-3) and, respectively, oligo-
nucleotide 660 (5-CGGGATCCCCTGGTCACTGTAAGGAGGT
GTTGGTTCTCCTAATCTTTAA-3 for mutations A50G and
U64C in Rz-Ke), oligonucleotide 662 (5-CGGGATCCCCTGGT
CACTGTAATGAGGTGTTGGTTCTCATAATCTTTAA-3 for mu-
tations A50U and U64A in Rz-Ki), oligonucleotide 663 (5-CGG
GATCCCCTGGTCACTGTAAGGAGGTGTTGGCTCTCCTAATC
TTTAA-3 for mutations A50G, U64C, and A55G in Rz-Kem),
and oligonucleotide 661 (5-CGGGATCCCCTGGTCACTGTAA
TGAGGTGTTGGCTCTCATAATCTTTAA-3 for mutations A50U,
U64A, and A55G in Rz-Kim). Oligonucleotide 659 introduces a
HindIII restriction site, and oligonucleotides 660 to 663 introduce
BstN1 and BamHI restriction sites. Prior to ligation into pTFMA,
PCR products were purified on low-melting 1% agarose gel, ex-
tracted with the QIAquick Gel Extraction kit (Qiagen S.A.) and
double-digested with HindIII and BamHI (according to manufac-
turer’s instructions). Plasmids were isolated from transformed E.
coli TG1 cells. In vitro transcription of 0.1 mg/mL BstN1 linearized
plasmids was performed for 4 h at 37°C in 40 mM Tris-HCl (pH
8.1 at 37°C), 30 mM MgCl2, 5 mM dithiothreitol, 0.01% Triton-
X100, 1 mM spermidine, and 4 mM each nucleoside triphosphate
and T7 RNA polymerase. The hammerhead ribozyme, which con-
tains four nucleotides complementary to the first four nucleotides
of the 5-end of the tRNA, cleaves the phosphodiester linkage
directly upstream of residue C1 of the tRNA. After phenol/chlo-
roform extraction, transcripts were purified to single nucleotide
resolution on denaturing 12% polyacrylamide/urea gels, electro-
eluted, and ethanol precipitated.
Preparation of native tRNALys
Human cybrid cells (homoplasmic for either wild-type, R2–1A, or
MERRF-mutated, R1-C3, human mt tRNALys gene) were grown,
mitochondria were isolated, and specific tRNAs were extracted by
hybridization to solid-phase oligonucleotide as previously de-
scribed (Chomyn et al. 1991; Helm et al. 1999a). Briefly, mito-
chondria were isolated from cybrid cells by differential centrifu-
gation and total mt tRNAs were obtained by subsequent extrac-
tion using guanidium isothiocyanate. Human mt tRNALys was
further purified by hybridization to a 5-biotinylated labeled 30-
mer, complementary to its 3-end as described (Helm et al. 1998).
tRNA was recovered from the streptavidin-coated beads by heat-
ing for 5 min at 80°C in 2 mM EDTA and immediately chilling on
ice. About 0.3 µg of native tRNALys were recovered from 3.3 g of
pelleted cells (corresponding to ∼1 L adherent cell-cultures).
Lysyl-tRNA synthetase
The human cytosolic histidine-tagged LysRS was purified as pre-
viously described (Shiba et al. 1997), using a nickel-nitrilotriacetic
acid resin (Qiagen) according to the manufacturer’s instructions.
Enzymatic activity for LysRS was 51 UE/mg (nanomoles of lysine
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incorporated per mg of protein per min), in aminoacylation con-
ditions as described below using E. coli total tRNAs as substrate.
Aminoacylation reactions
Aminoacylation reactions have been performed as described (Per-
ret et al. 1990; Shiba et al. 1997) in a medium containing 50 mM
HEPES-KOH (pH 7.5), 20 mM KCl, 10 mM MgCl2, 4 mM ATP,
0.1 µg/µL BSA, 20 µM [3H]-labeled lysine (specific activity of
∼1400 cpm/pmole), and adequate amounts of tRNA (0.1 to 10
µM) and LysRS (1 to 600 nM) at 37°C or 25°C. Before aminoac-
ylation, transcripts were renatured by heating for 2 min at 60°C
and slow cooling to room temperature. Kinetic parameters were
derived from Lineweaver-Burk plots. Because the concentration of
amino acid was subsaturating, only apparent kinetic parameters
are given. In all cases, two independent preparations of transcripts
have been done and at least two sets of experiments performed to
define kinetic parameters. If the variability in functional results
varied >10%–20%, a third preparation of molecules was done and
analyzed. Doing so, kinetic parameters differing by <10% were
obtained for each tRNA. The charging levels (optimal lysylation
plateaus) are expressed as percentages of charged tRNA versus
total amount of specific tRNA per experiment. For poor tRNA
substrates, direct determination of the ratio kcat/KM was estab-
lished as the slope of the linear plot of initial rate versus high tRNA
concentrations (Schulman and Pelka 1988).
Structural mapping in solution
5-Labeling and subsequent purification of tRNA transcripts were
carried out as previously described (Helm et al. 1998). Cleavage
with lead acetate was performed in 40 mM Tris-HCl (pH 7.5), 10
mM MgCl2, 40 mM NaCl, and 0.1 µg/µl carrier tRNA in the
presence of 0.15 mM Pb(OAc)2 for 10 to 30 min at 25°C. Reac-
tions were stopped by addition of 1 volume RNA loading buffer (8
M urea, 100 mM Tris-borate at pH 8.3, 10 mM EDTA). Modifi-
cation with diethylpyrocarbonate (DEPC) was performed in 50
mM sodium cacodylate (pH 8.0), 10 mM MgCl2, 300 mM KCl
(control, C, and native, N, conditions), or 50 mM sodium caco-
dylate (pH 8.0), 1 mM EDTA (semi-denaturing, SD, and dena-
turing, D, conditions), respectively. Aliquots of 50 000 cpm 5-
labeled RNA supplemented with 0.05 to 0.1 µg/µL carrier tRNA
were incubated with 5% (v/v) DEPC for 40 min at 25°C (N, SD)
or 4 min at 60°C (D), respectively. Reactions were stopped by
addition of 1 volume 0.6 M NaOAc (pH 7.0) and 20 µg carrier
tRNA and subsequent ethanol precipitation. Cleavage of RNA at
DEPC-modified adenine residues was done according to the
method of Peattie and Gilbert (1980). Cleavage products were
analyzed by denaturing separation on 12% PAGE as described
(Helm et al. 1998).
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